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Abstract
Lysozymes are ancient and important components of the innate immune system of animals that hydrolyze peptidoglycan,
the major bacterial cell wall polymer. Bacteria engaging in commensal or pathogenic interactions with an animal host have
evolved various strategies to evade this bactericidal enzyme, one recently proposed strategy being the production of
lysozyme inhibitors. We here report the discovery of a novel family of bacterial lysozyme inhibitors with widespread
homologs in gram-negative bacteria. First, a lysozyme inhibitor was isolated by affinity chromatography from a periplasmic
extract of Salmonella Enteritidis, identified by mass spectrometry and correspondingly designated as PliC (periplasmic
lysozyme inhibitor of c-type lysozyme). A pliC knock-out mutant no longer produced lysozyme inhibitory activity and
showed increased lysozyme sensitivity in the presence of the outer membrane permeabilizing protein lactoferrin. PliC lacks
similarity with the previously described Escherichia coli lysozyme inhibitor Ivy, but is related to a group of proteins with a
common conserved COG3895 domain, some of them predicted to be lipoproteins. No function has yet been assigned to
these proteins, although they are widely spread among the Proteobacteria. We demonstrate that at least two
representatives of this group, MliC (membrane bound lysozyme inhibitor of c-type lysozyme) of E. coli and Pseudomonas
aeruginosa, also possess lysozyme inhibitory activity and confer increased lysozyme tolerance upon expression in E. coli.
Interestingly, mliC of Salmonella Typhi was picked up earlier in a screen for genes induced during residence in macrophages,
and knockout of mliC was shown to reduce macrophage survival of S. Typhi. Based on these observations, we suggest that
the COG3895 domain is a common feature of a novel and widespread family of bacterial lysozyme inhibitors in gram-
negative bacteria that may function as colonization or virulence factors in bacteria interacting with an animal host.
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Introduction
Lysozymes (EC 3.2.1.17) hydrolyse the b-(1,4) glycosidic bond
between N-acetylmuramic acid and N-acetylglucosamine in
peptidoglycan, the major cell wall polymer in the Bacteria.
Peptidoglycan forms a network that surrounds the entire bacterial
cell, and its hydrolysis by lysozyme renders bacteria sensitive to
lysis driven by turgor pressure. Lysozymes are implicated in
defensive and offensive bactericidal systems in a wide range of
taxonomically diverse organisms including fungi, protozoa, plants,
invertebrate and vertebrate animals and even bacteriophages,
indicating their evolutionary success as bactericidal tools. Most
gram-negative bacteria are not susceptible to the action of
lysozyme alone because their outer membrane prevents access of
the enzyme to the peptidoglycan layer. However, this barrier has
been overcome in the innate immune systems of animals by the
production of accessory antibacterial proteins which permeabilize
the outer membrane, such as lactoferrin. In addition, some natural
lysozymes as well as chemically or genetically modified hen egg
white lysozyme (HEWL) have been reported to be active against
gram-negative bacteria even in the absence of such permeabilizers
[1–4].
In view of the widespread occurrence and effectiveness of
lysozymes as antibacterial agents, it is not surprising that bacteria
have in turn evolved mechanisms to evade or subvert this threat. A
bacterial lysozyme resistance mechanism that has been known for
long is peptidoglycan modification. Examples are the de-N-
acetylation of N-acetylglucosamine in Bacillus subtilis vegetative
cells [5], and O-acetylation of the C-6 hydroxyl group of N-
acetylglucosamine residues in Staphylococcus aureus and several other
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peptidoglycan-specific O-acetyltransferase encoded by oatA, and is
believed to contribute greatly to the persistence of pathogenic S.
aureus strains on the skin and mucosal surfaces [7]. A different
bacterial strategy to evade the bactericidal action of lysozyme that
has more recently emerged is the production of lysozyme
inhibitors. In group A streptococci, a protein first identified as
an inhibitor of the complement system and therefore designated as
SIC (streptococcal inhibitor of complement), was later also shown
to inhibit lysozyme [8]. However, since SIC does not have a very
high affinity for lysozyme (dissociation constant Kd = 85.4 mM),
and also binds to and inhibits several other components of the
innate immune system such as secretory leukocyte proteinase
inhibitor and b-defensins at higher affinity [8,9], it can not be
considered as a highly specific lysozyme inhibitor. A different
lysozyme inhibitor, showing high affinity (Kd = 1 nM), was
inadvertently identified during a systematic study of orphan gene
products in Escherichia coli [10]. The product of ykfE was shown to
strongly bind to and inhibit c-type lysozymes, which include
HEWL and human lysozymes, and was accordingly renamed Ivy
(Inhibitor of vertebrate lysozyme). Using Ivy-deficient and Ivy-
overexpressing E. coli strains, we demonstrated that Ivy contributes
to lysozyme resistance of E. coli when the bacteria are
simultaneously challenged with lactoferrin or with high hydrostatic
pressure to permeabilize their outer membrane [11], and these
findings fed speculations about a possible role for lysozyme
inhibitors in bacterial interactions with vertebrate hosts. Pleading
against such a role in a wide range of bacteria is the limited
distribution of Ivy homologs (only in a few proteobacterial species)
and in particular their apparent absence in the majority of gram-
negative pathogens.
However, until now no dedicated function-based screenings for
lysozyme inhibitors in bacteria have been reported, and thus the
existence of bacterial lysozyme inhibitors different from Ivy can
not be excluded. This possibility is supported by our recent
observation of lysozyme inhibitory activity in crude cell extracts of
Salmonella Typhimurium and S. Enteritidis which do not contain
an ivy homolog in their genome ([12] and unpublished
observation). In the current paper, we report the identification
of this component as a novel type of periplasmic proteinaceous
lysozyme inhibitor unrelated to Ivy and we demonstrate that this
inhibitor contributes to lysozyme resistance in S. Enteritidis.
Furthermore, two other members of the large but cryptic family of
proteins with which this novel inhibitor shares a common
structural motif are demonstrated to inhibit lysozyme, supporting
the functional annotation of this protein family as bacterial
lysozyme inhibitors.
Results
Isolation and identification of a HEWL-inhibitor from S.
Enteritidis
In previous work we tested the sensitivity of cell walls of different
gram-negative bacteria against several lysozymes [12]. To remove
the outer membranes from these cells and make their cell walls
accessible to lysozyme, we applied an extraction with chloroform-
saturated buffer. A side observation in this work was that this
procedure also allowed efficient extraction of the periplasmic
lysozyme inhibitor Ivy from E. coli cells since extracts from the
wildtype strain showed inhibitory activity against HEWL, while
those from the Ivy
2 strain did not. Interestingly, extracts from S.
Typhimurium also showed HEWL inhibition, although S.
Typhimurium does not contain an Ivy homolog, nor do any of
the other Salmonella serotypes from which a genome sequence is
available. This observation was extended to extracts of S.
Enteritidis (data not shown). Since we previously purified Ivy by
a single HEWL affinity chromatography step to more than 95%
purity starting from a periplasmic extract of E. coli overexpressing
Ivy from a plasmid [13], we used the same approach and the same
matrix (HEWL coupled to N-hydroxysuccinimide-activated Se-
pharose 4 Fast Flow resin) to isolate the putative lysozyme
inhibitor from wildtype S. Enteritidis. When the periplasmic
extract obtained from S. Enteritidis (inhibitory activity of 11.6 IU/
ml) was passed over the affinity column, the flow-through fraction
did no longer show HEWL inhibitory activity. The elution of the
bound proteins, with their corresponding inhibitory activity, is
shown in Figure 1. Two peaks of 27 and 20 milli absorption units
were detected at elution volumes of respectively 19 ml and 27 ml,
the latter coinciding with a single peak of HEWL inhibitory
activity (67 IU/ml). SDS-PAGE analysis of this active fraction
showed only a single band after Coomassie or silver staining
(Figure 1). Material recovered from a Coomassie band was
subjected to trypsin digestion and tandem mass spectrometry
analysis allowing to identify with high confidence peptides
(MASGANYEAIDK, MASGANYEAIDKNYTYK, TAEL-
VEGDDK and TAELVEGDDKPVLSNCSLAN) corresponding
to fragments of the predicted product of the SEN1802 open
reading frame in the genome sequence of S. Enteritidis PT4
(Wellcome Trust Sanger Institute, Cambridge UK; http://www.
sanger.ac.uk/). A SEN1802 homolog is present in S. Typhimur-
ium LT2 and all other sequenced Salmonella genomes (National
Centre for Biotechnology Information; http://www.ncbi.nlm.nih.
gov/). The function of this gene product is unknown but it carries
a predicted N-terminal signal peptide of 24 amino acids for Sec
dependent transport to the periplasm. This prediction is in good
agreement with our isolation of the protein from the periplasmic
cell fraction and with its supposed activity as a lysozyme inhibitor.
SEN1802 has two cysteines in its amino acid sequence for possible
disulfide bridge formation, a calculated pI of 4.76 and a predicted
molecular weight of 9981 Da (for 90 amino acid residues) after
cleavage of the signal peptide. This is less than our molecular
Author Summary
Lysozyme is an ancient bactericidal enzyme that is part of
the antibacterial defense system of vertebrate and
invertebrate animals. Bacteria colonizing or infecting an
animal host have developed various ways to overcome
lysozyme action, a recently proposed mechanism being
the production of lysozyme inhibitors. However, the only
high affinity bacterial lysozyme inhibitor known thus far is
produced only in few bacteria, and this raised questions
about their wider relevance in bacteria–host interactions.
We here report the discovery of a novel and distinct family
of bacterial lysozyme inhibitors that is widely distributed
among the Proteobacteria, including several major path-
ogens. The family comprises periplasmic as well as
membrane-bound inhibitors, and both types contribute
to lysozyme tolerance of bacterial cells, as we experimen-
tally demonstrate for the periplasmic inhibitor from
Salmonella Typhimurium and the membrane-bound inhib-
itors from Escherichia coli and Pseudomonas aeruginosa.
Interestingly, a gene encoding one of the newly identified
inhibitors has been previously found to promote macro-
phage survival of Salmonella Typhi. The widespread
occurrence of lysozyme inhibitors in bacteria is likely to
reflect their functional importance in a wide range of
bacteria–host interactions. As such, they are also attractive
novel targets for antibacterial drug development.
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deviation is not uncommon for acidic proteins and has been
ascribed to poor binding of SDS [14]. Because of its HEWL
inhibitory activity, we named the protein as PliC (periplasmic
lysozyme inhibitor of c-type lysozyme).
Overexpression and knock-out of pliC in S. Enteritidis
To investigate the function of PliC in S. Enteritidis, a PliC
knock-out (S. Enteritidis pliC) and PliC overexpression strain (S.
Enteritidis pliC (pAA510)) were constructed. The level of PliC
production by these strains in comparison to the wildtype strain
was evaluated by analyzing the lysozyme inhibitory activity of
crude periplasmic protein extracts (Figure 2). Knock-out of PliC
resulted in a strong reduction of inhibitory activity in extracts of S.
Enteritidis pliC (4.3 IU/ml) compared to wildtype extracts
(29.0 IU/ml). Since the open reading frame downstream of pliC
has an opposite orientation, this loss of inhibitory activity cannot
be due to a polar effect of the knock-out. Introduction of the
pAA510 plasmid in S. Enteritidis pliC rescued lysozyme inhibitory
activity (176.5 IU/ml when grown in the presence of 0.2%
arabinose to induce the cloned pliC gene. These results confirm
that the lysozyme inhibitory activity in the periplasmic extracts can
be ascribed to the PliC protein. It should be remarked that the
inhibitory activity of the wildtype extract in this experiment was
higher than in the extract used for chromatographical purification
(29.0 IU/ml versus 11.6 IU/ml). This is due to variability of yield
between different osmotic shock treatments (data not shown).
However, the yields of samples that were simultaneously processed
in a single osmotic shock treatment were reproducible for a
particular strain.
PliC protects S. Enteritidis against HEWL in the presence
of lactoferrin
Suspensions of late exponential phase wildtype, pliC knock-out
and pliC overexpression cells induced with arabinose were treated
with 3.0 mg/ml lactoferrin, 100 mg/ml lysozyme, or a combina-
tion of both, and survivors were enumerated after 24 h (Figure 3).
Most cells survived these treatments very well (inactivation levels
not exceeding twofold), except for S. Enteritidis pliC cells in the
presence of the lactoferrin - lysozyme mixture, which showed
almost 15-fold inactivation. Lactoferrin is known to sensitize gram-
negative bacteria to lysozyme and other antibacterial peptides by
assisting their penetration through the outer membrane. Although
the sensitizing action did not suffice to kill the wildtype S.
Enteritidis under the conditions of our experiment, the fact that
Figure 1. Purification of PliC from S. Enteritidis periplasmic extract by HEWL-affinity chromatography. Protein concentration in eluate
was monitored by absorption at 280 nm [A280] and expressed in milli absorption units [mAU] (—), inhibitory activity of fractions against HEWL was
monitored by inhibitor assay (-e-). Elution was done with a gradient of 0–2.0 M KCl in 0.1 M Tris, pH 12.0 (?2?2?). Photograph in inset shows SDS-
PAGE gel with molecular weight markers (lane 1, and indices in kDa at the left) and a concentrated fraction containing 0.163 mg/ml protein (without
BSA addition) and an inhibitory activity of 323 IU/ml, corresponding to a specific activity of 1982 U/mg (lane 2).
doi:10.1371/journal.ppat.1000019.g001
Figure 2. In vitro HEWL inhibitory activity of PliC from S.
Enteritidis. Lysis (expressed as OD600 against time) of M. lysodeikticus
cell suspension by 6.6 U/ml HEWL in the absence (-&-) and presence of
periplasmic protein extracts of S. Enteritidis pliC (1:2 diluted; -m-), S.
Enteritidis (1:10 diluted; —) and S. Enteritidis pliC (pAA510) (1:40 diluted;
-o-). Lysozyme inhibitory activity (IU/ml) of undiluted extracts is shown
in the table in inset. The control sample (—) consisted of phosphate
buffer instead of lysozyme solution added to M. lysodeikticus.
doi:10.1371/journal.ppat.1000019.g002
New Family of Lysozyme Inhibitors
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PliC were sufficient to protect S. Enteritidis cells against lysozyme.
Distribution of PliC relatives
An iterative search for sequences similar to the mature PliC
protein using Psi-Blast [15] revealed besides the homologs in other
Salmonella serotypes, similarity to proteins containing the conserved
domain COG3895 (Clusters of Orthologous Groups, [16] http://
www.ncbi.nlm.nih.gov/COG/). Proteins harboring this domain
are widespread among members of the Proteobacteria, except the
e-Proteobacteria. Representatives are found in at least 52 different
genera of the 155 completely sequenced genomes of all
Proteobacteria available as to date (December 2007) and
additionally occur in the Acidobacteria, Cyanobacteria and
Bacteroides groups. The vast majority of COG3895 proteins are
small proteins not containing other conserved protein domains
and are predicted to be either periplasmic proteins (like PliC) or
lipoproteins ([17], using the lipoprotein prediction tool available at
http://www.mrc-lmb.cam.ac.uk/genomes/dolop/), but their
function remains unknown. Also E. coli and Pseudomonas aeruginosa,
which already have an active Ivy type lysozyme inhibitor [10,18],
encode a COG3895 protein, respectively YdhA and PA0867.
These two proteins are predicted to be anchored to the
periplasmic side of the outer membrane [19,20]. Because of their
homology with PliC of Salmonella and their cellular localization in
the bacterial cell, these proteins were renamed as MliC
(membrane-bound lysozyme inhibitor of c-type lysozyme). This
designation already anticipates on the functionality of these
proteins as lysozyme inhibitors which will be demonstrated below.
Although both bacteria, like Salmonella, belong to the c-Proteo-
bacteria, the two predicted MliC proteins share only 32% (over 53
amino acids) and 27% (over 65 amino acids) identity with PliC,
and 38% identity (over 70 amino acids) with each other (Figure 4).
Because of this relatively large distance and because a 3-D
structure is available for MliC of E. coli (YdhA, [21]), MliC from E.
coli and P. aeruginosa were chosen as representatives to further
investigate the lysozyme inhibitory activity of the lipoprotein
subgroup within the COG3895 group of proteins.
In vitro HEWL-inhibitory activity of MliC proteins
mliC from P. aeruginosa and E. coli were cloned under control of
an arabinose inducible promoter (pAA520 and pAA530 respec-
tively) in an E. coli ivy mliC background, to avoid interference from
endogenous E. coli inhibitors. Lysozyme inhibitory activity was
measured in the periplasmic extracts and membrane fractions of
the overexpression strains after induction and compared to that of
the control strain E. coli ivy mliC without overexpression plasmid.
No significant differences in lysozyme inhibitory activity were
found in the periplasmic protein extracts (data not shown). On the
other hand, while only 6.3 IU/ml inhibitory activity was detected
in the membrane fraction of E. coli ivy mliC, much higher levels of
inhibitory activity were measured in the extracts upon induction of
MliC expression from P. aeruginosa (67.6 IU/ml) or MliC from E.
coli (40.7 IU/ml) (Figure 5). Therefore, we can conclude that both
MliC of P. aeruginosa and MliC of E. coli are HEWL-inhibitors.
It can also be seen in Figure 5, that knock-out of mliC in E. coli
had almost no influence on the level of inhibitory activity of the
membrane extracts (6.7 versus 6.3 IU/ml, for an ivy and an ivy
mliC strain respectively). This is in line with earlier reports that
mliC (previously ydhA) transcripts of E. coli are not detected under
normal laboratory growth conditions [22].
Figure 3. Sensitivity of S. Enteritidis strains to lysozyme in the
presence of lactoferrin. Inactivation (No/N) of S. Enteritidis pliC, S.
Enteritidis and S. Enteritidis pliC (pAA510) after 24 h of incubation with
10 mM Tris-HCl pH 7.0 (%), 100 mg/ml lysozyme (&), 3.0 mg/ml
lactoferrin (&) and lysozyme and lactoferrin together (&). Mean values
6 standard deviations (error bars) are shown (n=4). Lysozyme
treatments resulting in significant differences (p,0.01) compared to
the same treatments without lysozyme are marked with an asterisk.
doi:10.1371/journal.ppat.1000019.g003
Figure 4. Amino acid sequence alignment of new HEWL inhibitors. Amino acid sequence alignment (http://www.ebi.ac.uk/clustalw/, [37]) of
MliC from P. aeruginosa ( = PA0867 from P. aeruginosa PA01), MliC from E. coli ( = YdhA from E. coli MG1655) (both proteins containing the COG3895
domain) and PliC from S. Enteritidis ( = SEN1802 from S. Enteritidis). Residues that are identical in all sequences in the alignment are marked with ‘‘*’’
in the bottom row, conserved and semi-conserved substitutions with ‘‘:’’ and ‘‘.’’ respectively. The lipobox of the lipoproteins is underlined, while
cysteine residues of the mature protein are highlighted in grey.
doi:10.1371/journal.ppat.1000019.g004
New Family of Lysozyme Inhibitors
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growth inhibition of E. coli by HEWL
To investigate the actual contribution of the inhibitors to
bacterial HEWL resilience, E. coli ivy mliC was rendered sensitive to
HEWL by introducing a tolA mutation that increases its outer
membrane permeability. The resulting triple mutant was subse-
quently transformed with different plasmids that enable arabinose
induced expression of either Ivy from E. coli (pAA410), PliC from
S. Enteritidis (pAA510), MliC from P. aeruginosa (pAA520), and
MliC from E. coli (pAA530). Next, we compared the growth
inhibition by HEWL of these strains in the absence and in the
presence of arabinose in the medium. At a HEWL concentration
of 25 mg/ml, significant differences in optical density (OD600) and
in plate counts (CFU/ml) of the cultures were observed upon
induction of each inhibitor (Figure 6). Overexpression of Ivy, PliC
of S. Enteritidis, MliC of P. aeruginosa or MliC from E. coli increased
bacterial growth after 8 hours respectively 9, 7, 7 and 5-fold. A
control construct (pAA100) containing the gene for green
fluorescent protein (gfp) in the same vector and E. coli background,
showed no significant differences in optical density or plate counts
upon induction (data not shown). These results demonstrate that
besides Ivy, also at least three members of the newly identified
family of lysozyme inhibitors can effectively protect bacterial cells
against lysozyme when expressed at appropriate levels.
Discussion
In this work, we have identified a novel class of lysozyme
inhibitors different from Ivy, the lysozyme inhibitor discovered
Figure 5. In vitro HEWL inhibitory activity of MliC from P.
aeruginosa and E. coli. Lysis (expressed as OD600 against time) of M.
lysodeikticus cell suspension by 6.6 U/ml HEWL in the absence (-&-) and
presence of membrane protein extracts of E. coli ivy mliC (1:2 diluted;
-m-), E. coli ivy (1:2 diluted; —), E. coli ivy mliC (pAA520) expressing MliC
from P. aeruginosa (1:10 diluted; -%-) and E. coli ivy mliC (pAA530)
expressing MliC from E. coli (1:5 diluted; -o-). Lysozyme inhibitory
activity (IU/ml) of undiluted extracts is shown in the table in inset. The
control sample (—) consisted of phosphate buffer instead of lysozyme
solution added to M. lysodeikticus. The protein concentration of the
undiluted membrane protein extracts from the different strains was the
same (0.310 6 0.045 mg/ml).
doi:10.1371/journal.ppat.1000019.g005
Figure 6. Influence of HEWL inhibitors on HEWL growth inhibition. Growth curves (OD600)o fE. coli tolA ivy mliC harboring (A) pAA410
carrying Ivy from E. coli, (B) pAA510 carrying PliC from S. Enteritidis, (C) pAA520 carrying MliC from P. aeruginosa, and (D) pAA530 carrying MliC from E.
coli, in the presence of 25 mg/ml HEWL and with (-&-) or without (-%-) 0.02% arabinose. Bars represent viable cell numbers after 8 hours determined
by plate count (log CFU/ml). Mean values 6 standard deviations (error bars) are shown (n=3).
doi:10.1371/journal.ppat.1000019.g006
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of proteobacterial predicted periplasmic proteins or lipoproteins
which share a common COG3895 structural motif with unknown
function. We demonstrated lysozyme inhibitory activity for one
periplasmic (PliC from S. Enteritidis), as well as for two lipoprotein
members of this family (MliC from P. aeruginosa and from E. coli).
Although no function had hitherto been assigned to any of the
COG3895 proteins the 3-D solution structure of MliC from E. coli
has been recently resolved, featuring an 8-stranded b-barrel,
stabilized by a disulfide bond [21]. At the 3-D level, there is no
resemblance with Ivy, which adopts a central b-sheet made of 5
antiparallelb-strandsflankedontheconvexsidebytwoshorthelices
and on the concave side by an amphipathic helix [18]. The Cys
residues engaging in the disulfide bond in MliC from E. coli are
conserved in both PliC from S. Enteritidis and MliC from P.
aeruginosa, and in the majority of COG3895 proteins, suggesting that
they may be important for preserving conformational stability.
The existence and possible function of lysozyme inhibitors in
bacteria has not received much attention thus far. To our
knowledge, a systematic screen for bacterial lysozyme inhibitors
has not yet been conducted. This is surprising, given the important
role of lysozymes in antibacterial defense in all major eukaryotic
lineages, and the extensively documented existence of inhibitors of
various other glycosyl hydrolases. Particularly plants produce a
wide range of such inhibitors, for example against polygalacturo-
nases, xylanases, a-amylases and b-glucanases, to thwart microbial
attack. Therefore, the discovery in this work of a novel class of
bacterial lysozyme inhibitors and the wide distribution of
homologs of these inhibitors in the Proteobacteria may be
indicative for their functional importance, for example in
bacteria-host interactions. The location of the bacterial lysozyme
inhibitors either in the periplasm (Ivy and PliC from S. Enteritidis),
or anchored to the luminal face of the outer membrane (MliC
from E. coli and P. aeruginosa) is also consistent with a role in
protecting peptidoglycan from hydrolysis by exogenous lysozymes.
In at least one instance more direct evidence for a role in host
interaction exists. In Salmonella Typhi, expression of the mliC
homolog was induced in cells residing within macrophages and
knockout of mliC reduced macrophage survival [23]. Macrophages
are known to produce a battery of antibacterial peptides including
lysozyme and membrane permeabilizers, and hence the produc-
tion of one or more lysozyme inhibitors by intracellular pathogens
like S. Typhi makes sense from this point of view. The observed
increased lysozyme sensitivity of an S. Enteritidis pliC knockout in
the presence of 3.0 mg/ml of the outer membrane permeabilizing
protein lactoferrin (Figure 3) provides a relevant indication in this
context. Lactoferrin concentrations in this range occur in
secretions like tears, airway mucus or colostrum [24,25,26].
Moreover, Ivy and all three new HEWL-inhibitors identified in
this study suppressed growth inhibition by HEWL when
overexpressed in an E. coli MG1655 tolA ivy mliC strain (Figure 6).
The genomic context of the newly identified lysozyme inhibitor
genes also provides some interesting clues about their possible
function. Immediately upstream of pliC of S. Typhimurium are the
genespagC,pagDandmsgA,whichplayaroleinmacrophagesurvival
of S. Typhimurium. Furthermore, transcriptome analysis has
revealed that expression of pliC is controlled by SlyA, the same
transcriptional activator that controls expression of pagC and pagD
and that is necessary for virulence [27]. Based on its low GC
content, the region encompassing pagC and a number of its
immediate upstream genes was suggested to be acquired by lateral
gene transfer, as is often the case for virulence genes [28]. The pliC
gene,which isimmediatelydownstreamofpagC,alsohasamarkedly
lower GC content (42.0%) than the average of the LT2
chromosome (52.2%), and thus probably is an integral part of this
acquired genome fragment. Interestingly, the mliC gene is located
downstream of slyA in all sequenced Salmonella strains. Furthermore,
both in E. coli and in Salmonella, mliC or its homolog are adjacent to
ydhH, an open reading frame recently renamed to anmK because it
encodes an anhydro N-acetyl muramic acid kinase involved in
recycling of murein [29]. This allows speculation on a possible role
of MliC in murein recycling, for example by controlling excessive
hydrolysis of the murein backbone by lytic transglycosylases.
However, at present we do not know whether the latter enzymes
are inhibited by MliC or any of the other COG3895 proteins.
C-type lysozymes (e.g. HEWL or human lysozyme) are the
major lysozymes produced by most vertebrates. In addition, all
vertebrates have genes encoding g-type lysozyme. While the
importance of the latter is not clear in man, it is the dominant type
in some birds and it also occurs in fish species. A third type of
lysozyme, called i-type, is characteristic for invertebrate animals
such as arthropods, molluscs, nematodes etc. [30]. Neither PliC
from S. Enteritidis, nor MliC from E. coli or P. aeruginosa have
inhibitory activity against g-type lysozyme from goose egg white
(data not shown). Ivy, in contrast, is active against goose egg white
lysozyme [13] but not against g-type lysozyme from the
urochordate Oikopleura dioica and i-type lysozyme from the scallop
Chlamys islandica [31]. Given the existence and widespread
occurrence of two types of c-type-specific lysozyme inhibitors in
Proteobacteria, we anticipate that additional inhibitor classes
specific against other types of lysozymes are also likely to be
produced in bacteria. Screening of crude periplasmic extracts of a
diverse range of bacteria for inhibitory activity against these g- and
i-type lysozymes seems to corroborate this assumption (unpub-
lished results), but definitive confirmation will have to await
isolation and identification of the putative inhibitors.
The possible effect of bacterial lysozyme inhibitors in bacterial
pathogenesis may even extend beyond neutralizing the direct
antibacterial effect of lysozyme.Peptidoglycan has recently emerged
as a powerful effector of the innate immune system through
interactionwithspecifichost receptors.Theactualelicitormolecules
are specific muropeptide fragments derived from peptidoglycan by
bacterial and/or host lytic enzymes [32,33]. This system of pattern
recognition is believed to allow the host to distinguish pathogenic
from non-pathogenic bacteria and to maintain itsimmune functions
at an appropriate level. Malfunctioning of this system has been
linked to chronic immune-related diseases such as inflammatory
bowel disease and Crohn’s disease. By interfering with the
fragmentation of peptidoglycan by host lysozymes, bacterial
lysozyme inhibitors can be anticipated to influence this system,
and thus to play a potential role in these immune related
pathologies. Provided that their role in bacterial pathogenesis can
be further substantiated, bacterial lysozyme inhibitors may
constitute an attractive new target for the development of anti-
inflammatory and/or immunomodulating drugs.
In conclusion, we have identified a novel family of bacterial
lysozyme inhibitors that contribute to bacterial lysozyme resistance
and that have widespread homologs in gram-negative bacteria.
Further study of these inhibitors will not only improve our
understanding of bacteria-host interactions, lysozyme inhibitors
may also turn out to be interesting novel targets for drug
development.
Materials and Methods
Bacterial strains, plasmids, and culture conditions
Bacterial strains and plasmids used in this study are listed in
Table 1. Construction of mutants and plasmids is discussed in Text
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electroporation.
All strains were originally cultured on Luria Bertani (LB; 10 g/l
trypton, 5 g/l yeast extract, 5 g/l NaCl) agar plates and incubated
at 37uC for 21 h. Overnight broth cultures were obtained by
inoculating a single colony into LB broth containing appropriate
antibiotics and incubating at 37uC for 21 h with aeration.
Antibiotics (Sigma-Aldrich, Bornem, Belgium) were added
when necessary to obtain the following final concentrations:
100 mg/ml ampicillin, 50 mg/ml kanamycin or 20 mg/ml
chloramphenicol.
Purification of HEWL-inhibiting proteins
For the purification of PliC, 500 ml cultures of S. Enteritidis
ATCC 13076 were grown on a rotary shaker to stationary phase
(21 h, shaking at 200 rpm) in LB at 37uC. Periplasmic cell extracts
were then prepared by a gentle cold osmotic shock procedure as
described earlier [13], and stored at 220uC until further analysis.
Lysozyme binding inhibitors were isolated from this periplasmic
cell fraction on an A ¨KTA-FPLC platform (Amersham Pharmacia
Biotech, Upsalla, Sweden) by affinity chromatography using
immobilized HEWL as a ligand as described earlier for the Ivy
protein [13], except that 100 ml of crude extract was loaded rather
than 25 ml, and fractions of 5.0 ml rather than 2.0 ml were
collected. The fractions were collected in tubes containing 300 ml
of 1.0 M Tris-HCl pH 8.0 to neutralize the high pH of the elution
buffer (pH 12.0), and bovine serum albumin (BSA, Sigma-Aldrich)
was added to a final concentration of 0.5 mg/ml to stabilize the
purified protein unless the samples were used for SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE). Fractions were then
desalted by dialysis against 10 mM potassium phosphate buffer
pH 7.0 (12 kDa cut off, Sigma-Aldrich) and stored at 220uC until
further use.
After purification, protein purity was checked with SDS-PAGE,
conducted according to [34] with a 15% separating gel and a 4%
stacking gel. Samples were prepared by boiling for 3 min in the
presence of 1% ß-mercaptoethanol and 1% SDS. Gels were
stained with Coomassie blue R 250 (Sigma-Aldrich), and, if higher
sensitivity was desired, destained and subsequently silver-stained
following the procedure of [35].
For the isolation of MliC of P. aeruginosa or E. coli, cultures of E.
coli ivy mliC harboring plasmid pAA520 or pAA530 respectively,
were grown overnight at 37uC in LB with ampicillin (100 mg/ml,
Sigma-Aldrich), diluted 1/100 in fresh LB without antibiotics,
induced with 0.2% (w/v) L2(+)-arabinose after 4 hours of growth,
and further incubated at 37uC until stationary phase. Portions of
200 ml were subsequently harvested, resuspended in 10 ml
10 mM Tris-HCl pH 8 and lysed by three cycles of freezing and
thawing followed by sonication (363 min, amplitude 40%, pulses
5 s on/5 s off). These suspensions were centrifuged for 1 hour at
100.0006g (4uC). The resulting pellet was resuspended in 10 ml
10 mM Tris-HCl buffer (pH 6.8) supplemented with 1.0 M NaCl,
and sedimented again as described above. The membrane-bound
proteins were then extracted using 2% Triton X-100 in a 10 mM
Tris-HCl buffer (pH 6.8) supplemented with 10 mM MgCl2 and
150 mM NaCl and separated from insoluble material by
centrifugation (1 hour at 100.0006g,4 uC).
Protein identification by mass spectrometry
Active fractions containing the purified inhibitor protein were
lyophilized, redissolved and subjected to SDS-PAGE and Coomas-
sie staining. A gel fragment from the band corresponding to the
inhibitor was trypsin-digested according to the method of [36], and
the digests were then analyzed by electrospray tandem mass
spectrometry on a LCQ Classic (ThermoFinnigan, San Jose,
California) ion trap mass spectrometer equipped with a nano-liquid
Table 1. Bacterial strains and plasmids used in this study.
Characteristics Reference or source
Strains
Salmonella Enteritidis
wildtype ATCC 13076 ATCC
pliC (*) ATCC 13076 pliC::Cm This study
Escherichia coli
wildtype MG1655 [38]
mliC(**) MG1655 mliC::Kn (FB20404) [39]
ivy MG1655 ivy::Cm This study
ivy mliC MG1655 ivy::Cm mliC::Kn This study
tolA ivy mliC MG1655 DtolA ivy::Cm mliC::Kn This study
Pseudomonas aeruginosa
wildtype PAO1 [40]
Plasmids
pAA100 gfp gene under PBAD control, pFPV25 backbone, Ap
R [41]
pAA410 ivy gene of E. coli under PBAD control, pFPV25 backbone, Ap
R [11]
pAA510 pliC gene of S. Enteritidis under PBAD control, pFPV25 backbone, Ap
R This study
pAA520 mliC gene of P. aeruginosa (***) under PBAD control, pFPV25 backbone, Ap
R This study
pAA530 mliC gene of E. coli under PBAD control, pFPV25 backbone, Ap
R This study
*pliC = SEN1802 from S. Enteritidis PT4 genome (www.sanger.ac.uk).
**mliC of E. coli = ydhA from E. coli MG1655 genome (www.ncbi.nlm.nih.gov).
***mliC of P. aeruginosa = PA0867 from P. aeruginosa PAO1 genome (www.ncbi.nlm.nih.gov).
doi:10.1371/journal.ppat.1000019.t001
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device. Tandem mass spectrometry data were searched using
MASCOT (Matrix Sciences, London, U.K.) and SEQUEST
(ThermoFinnigan) against the GenBank non-redundant protein
database.
Determination of HEWL inhibitory activity
Freeze-dried M. lysodeikticus ATCC4698 cells (Sigma-Aldrich)
were resuspended at 0.5 mg/ml either in appropriate dilutions of
the bacterial crude extracts, purified column fractions or in
potassium phosphate buffer (10 mM, pH 7.0) with 0.5 mg/ml
Bovine Serum Albumine (BSA) for the controls. Thirty mlo f
66 U/ml HEWL (Hen Egg White Lysozyme; Fluka, 66000 U/mg
protein) in potassium phosphate buffer (10 mM, pH 7.0) was then
added to 270 ml of these suspensions and cell lysis was followed
during 2 h at 25uC as the decrease in optical density (OD600) using
a Bioscreen C Microbiology Reader (Labsystems Oy, Helsinki,
Finland). In the absence of inhibitor, this procedure resulted in a
linear OD600 decrease of 0.27 6 0.04 over 2 h. The percentage
inhibition (I) for each column fraction was calculated as:
I~
L0{L ðÞ { R0{R ðÞ
L0{L ðÞ { B0{B ðÞ
x 100 % ðÞ
with L0 2 L, R0 2 R and B0 2 B representing the OD600
decrease over a period of 2 h of the M. lysodeikticus suspensions
respectively in the presence of lysozyme but with buffer instead of
a bacterial extract/column fraction, in the presence of the
bacterial extract/column fraction and lysozyme, and in the
presence of the bacterial extract/column fraction but with buffer
instead of lysozyme. Inhibitory activity was expressed in inhibitory
units, with one unit being the amount of inhibitor that is needed to
decrease the lysozyme activity by 50% under the above assay
conditions.
Sensitivity of S. Enteritidis to lysozyme in the presence of
lactoferrin
S. Enteritidis, S. Enteritidis pliC and S. Enteritidis pliC (pAA510)
cultures were grown overnight in LB with ampicillin and/or
chloramphenicol when appropriate, diluted 1/100 in fresh LB
without antibiotics, induced with 0.2% (w/v) L2(+)-arabinose
(Fluka, Buchs, Switzerland), and incubated further. Arabinose
served only to induce pliC expression from plasmid pAA510, but
was also added to cultures of strains not carrying this plasmid to
ensure identical culture conditions for all strains in the experiment.
At an optical density (OD600) of 0.6 (5.10
8 6 1.10
8 CFU/ml), cells
were harvested by centrifugation (38006g, 5 min) and subse-
quently resuspended in the same volume of Tris-HCl buffer
(10 mM; pH 7.0) without and with lactoferrin (gift from Morinaga
Milk Industries, Kanagawa, Japan; 3.0 mg/ml final concentration)
and/or HEWL (Fluka, 66000 U/mg protein; 100 mg/ml final
concentration). Samples were serially diluted in sterile Tris-HCl
buffer (10 mM; pH 7.0) at the beginning and after 24 hours of
treatment, and plated on LB agar plates to determine the degree of
inactivation. Inactivation was expressed as a viability reduction
factor, No/N, with No and N respectively the colony counts at the
beginning and after 24 hours of treatment.
Lysozyme growth inhibition in vivo
Precultures of E. coli MG1655 tolA ivy mliC harboring plasmid
pAA410, pAA510, pAA520, or pAA530 were grown overnight in
LB broth containing ampicillin, kanamycin and chloramphenicol.
Subsequently, cultures were diluted (1/100) in duplicate in fresh LB
containing ampicillin, and after three hours of growth (exponential
phase), either H2O or 0.02% L2(+)-arabinose was added, resulting
in control and induced precultures respectively. These cultures were
further grown to stationary phase to allow inhibitor expression.
Subsequently, test tubes containing 4 ml LB with ampicillin, and
either water or 0.02% L2(+)-arabinose and 25 mg/ml HEWL were
inoculated (1/100) with the control and induced E. coli precultures
respectively. These cultures were grown at 37uC during 10 hours.
Each hour the OD600 was determined using a Multiscan RC
(Thermo Scientific, Zellik, Belgium). After 8 hours the viable cell
number was enumerated by plating on LB agar.
List of geneID numbers
From E. coli MG1655: ivy (before ykfE): 946530 (Gene Entrez),
mliC (before ydhA): 946811 (Gene Entrez), tolA: 946625 (Gene
Entrez); From P. aeruginosa: mliC (before PA0867): 882238 (Gene
Entrez); From Salmonella Enteritidis: pliC: SEN1802 (http://www.
sanger.ac.uk/).
Supporting Information
Text S1 The construction of the S. Enteritidis pliC knock-out
mutant, the E. coli ivy mliC mutant, the E. coli tolA ivy mliC mutant
and the construction of the plasmids pAA510, pAA520 and
pAA530 is described.
Found at: doi:10.1371/journal.ppat.1000019.s001 (0.04 MB
DOC)
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